138 HER2CLIMB-05: A Randomized, Double-blind, Phase 3 Study of Tucatinib Versus Placebo Added to Trastuzumab and Pertuzumab as Maintenance Therapy for HER2+ Metastatic Breast Cancer
ByErika P. Hamilton, MD,Giuseppe Curigliano,Miguel Martin, MD, PhD,Florence Lerebours,Junji Tsurutani,Marie-France Savard,Katarzyna J. Jerzak, MD, MSc, FRCPC,Xichun Hu,Luciana Carla Martins de Aquino Pimentel,Ciara C. O’Sullivan,Eriko Tokunaga,Alicia Okines,Chiun-Sheng Huang,William Jacot,Joohyuk Sohn,Eduardo Cronemberger Silva,Volkmar Mueller,Helene Viala,Shan Yang,Giovanna Granata,Qi Shen,Libero Santarpia,Veronique Dieras